Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Animal biochemistry --- Bombesin --- BOMBESIN --- PEPTIDES --- Derivatives --- Physiological effect --- Congresses. --- Analogs & derivatives --- physiology --- Physiology --- Peptides --- Congresses

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer --- Hormone therapy --- Somatostatin --- Agonists --- Therapeutic use --- Bombesin --- Antagonists --- SOMATOSTATIN --- BOMBESIN --- NEOPLASMS --- ANALOGS & DERIVATIVES --- PHARMACOLOGY --- ANTAGONISTS AND INHIBITORS --- DRUG THERAPY --- DIAGNOSIS

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Obesity --- Satiety Response --- Cholecystokinin --- Satiation --- Bombesin --- drug therapy --- drug effects --- pharmacology --- drug effects --- pharmacology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Alpha-msh. --- Behavior. --- Bombesin-like peptides. --- Central nervous-system. --- Corticotropin-releasing-factor. --- Ethology. --- Gerbil meriones-unguiculatus. --- Grooming. --- Macaques macaca-fascicularis. --- Melanocyte-stimulating hormone. --- Mongolian gerbil. --- Neurobiology. --- Review. --- Rhesus-monkeys. --- Substance-p. --- Time.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Identification and development of cancer biomarkers and targets have greatly accelerated progress towards precision medicine in oncology. Studies of tumor biology have not only provided insights into the mechanisms underlying carcinogenesis, but also led to discovery of molecules that have been developed into cancer biomarkers and targets. Multi-platforms for molecular characterization of tumors using next-generation genomic sequencing, immunohistochemistry, in situ hybridization, and blood-based biopsies have greatly expanded the portfolio of potential biomarkers and targets. These cancer biomarkers have been developed for diagnosis, early detection, prognosis, and prediction of treatment response. The molecular targets have been exploited for anti-cancer therapy and delivery of therapeutic agents. This Special Issue of Biomedicines focuses on recent advances in the discovery, characterization, translation, and clinical application of cancer biomarkers and targets in malignant diseases of the digestive system. The goal is to stimulate basic and translational research and clinical collaboration in this exciting field with the hope of developing strategies for prevention and early detection/diagnosis of cancer in digestive organs, and improving therapeutic and psychosocial outcomes in patients with these malignant diseases.

n/a --- liver graft injury --- HFE --- neurokinin --- chemotherapy --- intestinal tumors --- therapeutic targets --- biliary tract carcinoma --- hepatocellular carcinoma --- clinical trial --- cell adhesion molecules --- colorectal cancer --- biomarkers --- phenotypic mosaics --- gastrointestinal oncology --- Asian Cancer Research Group (ACRG) --- biomarker --- psychosocial support --- precision therapy --- pancreatic carcinoma --- precision medicine --- Liver transplantation --- predictive biomarkers --- CD274 --- cholecystokinin --- The Cancer Genome Atlas (TCGA) --- gastrin --- pembrolizumab --- immunotherapy --- gastrin-releasing peptide --- stereotactic body radiation therapy --- immunohistochemistry --- gastric carcinoma --- liver transplant --- CAM invasion assay --- intragraft gene expression profiles --- molecular profiling --- targeted therapy --- neurotensin --- intestinal disorder --- ramucirumab --- next-generation sequencing --- colorectal carcinoma --- tumor progenitor --- circulating tumor cells --- gastrointestinal malignancies --- bombesin --- trastuzumab --- somatostatin --- zebrafish --- G protein–coupled receptors --- G protein-coupled receptors